Вакцинопрофилактика у больных с хроническим лимфолейкозом

Актуальность. Инфекции являются наиболее частым осложнением хронического лимфолейкоза (ХЛЛ), согласно регистровым исследованиям, они становятся причиной смерти у 10–20% больных. Благодаря новым методам лечения ХЛЛ смертность, обусловленная прогрессией, снижается, тогда как летальность от инфекций в последние десятилетия остается постоянной.

Цель – анализ эффективности вакцинопрофилактики у пациентов с ХЛЛ по опубликованным данным, изучение предикторов неэффективности вакцинации, анализ текущих рекомендаций.

Заключение. Механизмы иммунной дисфункции при ХЛЛ различны и связаны как с собственно заболеванием, так и с проводимой терапией. Результаты многочисленных исследований свидетельствуют о том, что у пациентов с ХЛЛ имеется неадекватный ответ на большинство вакцин, применяемых по стандартным схемам в общей популяции. Вакцинация у пациентов с ХЛЛ остается слабо разработанной темой. Необходимо проведение дополнительных клинических исследований с целью повышения эффективности вакцинации больных ХЛЛ

1. Molica S. Infections in Chronic Lymphocytic Leukemia: Risk Factors, and Impact on Survival, and Treatment. Leuk Lymphoma. 1994;13:203–14. DOI:10.3109/10428199409056283.

2. da Cunha-Bang C., Simonsen J., Rostgaard K., et al. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016;6(11):e499. DOI:10.1038/bcj.2016.105.

3. Дмитриева Е.А., Никитин Е.А., Маркова Е.Е., et al. Частота и факторы, предрасполагающие к инфекциям, у больных хроническим лимфолейкозом, получающих ибрутиниб. Клиническая онкогематология. 2019;12(4):438–48. DOI:10.21320/2500-2139-2019-12-4-438-448.

4. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Am Soc Hematol Educ Progr. 2008;(Cmv):450–6. DOI:10.1182/asheducation-2008.1.450.

5. Steininger C., Rassenti L.Z., Vanura K., et al. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest. 2009;39(6):497–506. DOI:10.1111/j.1365-2362.2009.02131.x.

6. Andersen M.A., Niemann C.U., Rostgaard K., et al. Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study. Clin Infect Dis. 2020;(Xx):1–9. DOI:10.1093/cid/ciaa090.

7. Chiorazzi N., Rai K.R., Ferrarini M. Chronic Lymphocytic Leukemia. New English J Med. 2005;352:804–15. DOI:10.1002/9781444300857.ch36.

8. Seifert M., Sellmann L., Bloehdorn J., et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183–98. DOI:10.1084/jem.20120833.

9. ten Hacken E., Burger J.A. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta - Mol Cell Res. 2016;1863(3):401–13. DOI:10.1016/j.bbamcr.2015.07.009.

10. Lagneaux L., Delforge A., Bron D., et al. Chronic lymphocytic leukemia (CLL) B-lymphocytes but not normal B-lymphocytes are rescued from apoptosis by contact with bone marrow stromal cells. Blood. 1998;91(7):2387–96.

11. Morrison V.A. Infectious Complications in Patients With Chronic Lymphocytic Leukemia : Pathogenesis , Spectrum of Infection , and Approaches to Prophylaxis. Clin Lymphoma Myeloma Leuk. 2009;9(5):365–70. DOI:10.3816/CLM.2009.n.071.

12. Palma M., Gentilcore G., Heimersson K., et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102(3):562–72. DOI:10.3324/haematol.2016.151100.

13. Kontoyiannis D.P., Georgiadou S.P., Wierda W.G., et al. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(8):1730–3. DOI:10.3109/10428194.2012.750723.

14. Maffei R., Bulgarelli J., Fiorcari S., et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013;98(7):1115–23. DOI:10.3324/haematol.2012.073080.

15. Huergo-Zapico L., Acebes-Huerta A., Gonzalez-Rodriguez A.P., et al. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia.Correlation with progressive disease. PLoS One. 2014;9(10). DOI:10.1371/journal.pone.0108326.

16. Panayiotidis P., Jones D., Ganeshaguru K., et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996;92(1):97–103. DOI:10.1046/j.1365-2141.1996.00305.x.

17. Pedersen I.M., Kitada S., Leoni L.M., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002;100(5):1795–801. DOI:10.1182/blood.v100.5.1795.h81702001795_1795_1801.

18. Herishanu Y., Pérez-Galán P., Liu D., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563–74. DOI:10.1182/blood-2010-05-284984.

19. Kurtova A. V., Balakrishnan K., Chen R., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: Development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441–50. DOI:10.1182/blood-2009-07-233718.

20. Moreira J., Rabe K.G., Cerhan J.R., et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27(1):136–41. DOI:10.1038/leu.2012.187.

21. Agency E.M. Guideline on Core SmPC for Human Normal Immunoglobulin for Intravenous Administration (IVIg): EMA (2018) [Internet]. 2018.

22. Raanani P.I.A., Gafter-gvili A., Paul M., et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma : systematic review and meta-analysis. 2009;50(May):764–72. DOI:10.1080/10428190902856824.

23. Füst G., Miszlay Z., Czink E., et al. C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance. Immunol Lett. 1987;14(3):255–9. DOI:10.1016/0165-2478(87)90110-6.

24. Middleton O., Cosimo E., Dobbin E., et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia. 2015;29(1):107–14. DOI:10.1038/leu.2014.146.

25. Forconi F., Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;125(5). DOI:10.1182/blood-2015-03.

26. Rossi D., Sozzi E., Puma A., et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol. 2009;146(1):64–75. DOI:10.1111/j.1365-2141.2009.07711.x.

27. Andersen M.A., Eriksen C.T., Brieghel C., et al. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: A danish nationwide cohort study. Haematologica. 2018;103(7):e300–3. DOI:10.3324/haematol.2017.182006.

28. Rozman C., Montserrat E., Vinolas N. Serum lmrnunoglobulins in B-Chronic Lymphocytic Leukemia. Cancer. 1988;61:279–83.

29. Anaissie E.J., Kontoyiannis D.P., O’Brien S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129(7):559–66. DOI:10.7326/0003-4819-129-7-199810010-00010.

30. Gafter-Gvili A., Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57(3):512–9. DOI:10.3109/10428194.2015.1110748.

31. McLaughlin P., Grillo-López A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–33. DOI:10.1200/JCO.1998.16.8.2825.

32. Rossi D., Shadman M., Condoluci A., et al. How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. HemaSphere. 2020;4(4):e432. DOI:10.1097/hs9.0000000000000432.

33. Munir T., Brown J.R., O’Brien S., et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–63. DOI:10.1002/ajh.25638.

34. Davids M.S., Hallek M., Wierda W., et al. Comprehensive safety analysis of Venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371–9. DOI:10.1158/1078-0432.CCR-17-3761.

35. Bayas J.M., Vilella A., Bertran M.J., et al. Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary? Epidemiol Infect. 2001;127(3):451–60. DOI:10.1017/s095026880100629x.

36. Van der Wielen M., Van Damme P., Chlibek R., et al. Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors. Vaccine. 2006;24(26):5509–15. DOI:https://doi.org/10.1016/j.vaccine.2006.04.016.

37. Wolters B., Junge U., Dziuba S., et al. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21(25):3623–8. DOI:https://doi.org/10.1016/S0264-410X(03)00399-2.

38. McElhaney J.E., Upshaw C.M., Hooton J.W., et al. Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults. Vaccine. 1998;16(18):1742–7. DOI:https://doi.org/10.1016/S0264-410X(98)00133-9.

39. Bernstein E.D., Gardner E.M., Abrutyn E., et al. Cytokine production after influenza vaccination in a healthy elderly population. Vaccine. 1998;16(18):1722–31. DOI:https://doi.org/10.1016/S0264-410X(98)00140-6.

40. Hainz U., Jenewein B., Asch E., et al. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine. 2005;23(25):3232–5. DOI:https://doi.org/10.1016/j.vaccine.2005.01.085.

41. Gergen P.J., McQuillan G.M., Kiely M., et al. A Population-Based Serologic Survey of Immunity to Tetanus in the United States. N Engl J Med. 1995;332(12):761–7. DOI:10.1056/NEJM199503233321201.

42. Rubins J.B., Puri A.K.G., Loch J., et al. Magnitude, Duration, Quality, and Function of Pneumococcal Vaccine Responses in Elderly Adults. J Infect Dis. 1998;178(2):431–40. DOI:10.1086/515644.

43. Konradsen H., Henrichsen J. Antibody Response to Pneumococcal Vaccination in the Elderly. Zentralblatt für Bakteriol. 1991;275(1):94–9. DOI:https://doi.org/10.1016/S0934-8840(11)80772-3.

44. McElhaney J.E., Zhou X., Talbot H.K., et al. The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine. 2012;30(12):2060–7. DOI:https://doi.org/10.1016/j.vaccine.2012.01.015.

45. Pleyer C., Wiestner A., Sun C. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59(12):2792–800. DOI:10.1080/10428194.2018.1457147.

46. Varughese T., Taur Y., Cohen N., et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies. Clin Infect Dis. 2018;67(5):687–692. DOI:10.1093/cid/ciy175.

47. Williams A.L.M., Baran A.M., Meacham P.J., et al. Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma. 2018;59(3):625–32. DOI:10.1080/10428194.2017.1347931.

48. Teh B.W., Tam C.S., Handunnetti S., et al. Infections in patients with chronic lymphocytic leukaemia : Mitigating risk in the era of targeted therapies. Blood Rev. 2018;0–1. DOI:10.1016/j.blre.2018.04.007.

49. Matanock A., Lee G., Gierke R., et al. Use of 13-Valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the advisory committee on immunization practices (ACIP). Am J Transplant. 2013;13(1):232–5. DOI:10.1111/ajt.12073.

50. Backhaus E., Berg S., Andersson R., et al. Epidemiology of invasive pneumococcal infections: Manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16(1):1–12. DOI:10.1186/s12879-016-1648-2.

51. Larson D.L., Tomlinson L.J. Quantitative antibody studies in man. III. Antibody response in leukemia and other malignant lymphomata. J Clin Invest. 1952;32(4):317–21. DOI:10.1172/JCI102741.

52. Shildt R.A., Boyd J.F., Mccracken J.D., et al. Antibody Response to Pneumococcal Vaccine in Patients With Solid Tumors and Lymphomas. Med Pediatr Oncol. 1983;11:305–9.

53. Shaw r.k., Szwed c., Boggs d.r., et al. Infection and Immunity in Chronic Lymphocytic Leukemia. Arch Intern Med. 1960;106:467–78. DOI:10.1001/archinte.1960.03820040005002.

54. Hartkamp A., Mulder A.H.L., Rijkers G.T., et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. 2001;19:1671–7.

55. Sinisalo M., Aittoniemi J., Oivanen P., et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001.

56. Velden A.M.T. Van Der, Velzen-blad H. Van, Claessen A.M.E. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. Eur J Haematol. 2007;(10):47–52. DOI:10.1111/j.1600-0609.2007.00862.x.

57. Safdar A., Rodriguez G.H., Rueda A.M., et al. Multiple-dose Granulocyte-Macrophage–Colony-stimulating Factor Plus 23-valent Polysaccharide Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia. 2015;113(2):383–7. DOI:10.1002/cncr.23561.Multiple-dose.

58. Sinisalo M., Vilpo J., It M., et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia akev ¨. 2007;82–7. DOI:10.1016/j.vaccine.2007.10.053.

59. Pasiarski M., Rolinski J., Grywalska E. Antibody and Plasmablast Response to 13- Valent Pneumococcal Conjugate Vaccine in Chronic Lymphocytic Leukemia Patients – Preliminary Report. 2014;1–14. DOI:10.1371/journal.pone.0114966.

60. Svensson T., Kättström M., Hammarlund Y., et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine. 2018;1–7. DOI:10.1016/j.vaccine.2018.05.012.

61. Mauro F.R., Diana G., Galluzzo C.M., et al. Response to the conjugate pneumococcal vaccine ( PCV13 ) in patients with chronic lymphocytic leukemia ( CLL ). Leukemia. 2020; DOI:10.1038/s41375-020-0884-z.

62. Andrick B., Alwhaibi A., DeRemer D., et al. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2018;182(5):712–4. DOI:10.1111/bjh.14855.

63. Никитин Е.А., Бялик Т.Е., Зарицкий А.Ю. и др. Хронический лимфоцитарный лейкоз/лимфома из малых лимфоцитов. Клинические рекомендации. Современная Онкология. 2020; 22 (3): 24–44. DOI: 10.26442/18151434.2020.3.200385

64. Чучалин А.Г., Брико Н.И., Авдеев С.Н. и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34. DOI:10.18093/0869-0189-2019-29-1-19-34

65. Lindström V., Aittoniemi J., Salmenniemi U., et al. Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia. Hum Vaccines Immunother. 2018;14(6):1471–4. DOI:10.1080/21645515.2018.1436424.

66. Lindström V., Aittoniemi J., Salmenniemi U., et al. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia. Hum Vaccin Immunother. 2019;0(0):1–4. DOI:10.1080/21645515.2019.1627160.

67. Ochoa-Grullón J., Benavente Cuesta C., Pérez López C., et al. Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies. Clin Immunol. 2020;210:108307. DOI:10.1016/j.clim.2019.108307.

68. Bonilla F.A., Khan D.A., Ballas Z.K., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1178–86. DOI:10.1016/j.jaci.2015.04.049.

69. Pulvirenti F., Milito C., Cavaliere F.M., et al. IGA Antibody Induced by Immunization With Pneumococcal Polysaccharides Is a Prognostic Tool in Common Variable Immune Deficiencies. Front Immunol. 2020;11:1283. DOI:10.3389/fimmu.2020.01283.

70. Kipps T.J., Stevenson F.K., Wu C.J., et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;3(Cll). DOI:10.1038/nrdp.2016.96.

71. Cheuk D.K.L., Chiang A.K.S., Lee T.L., et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev. 2007;(2). DOI:10.1002/14651858.CD006505.

72. Gribabis D. Influenxa virus vaccine in B-cell chronic lymphocytic leukemia patients. Acta Haematol. 1994;

73. Bucalossi A., Giuseppe M. Immunological Response to Influenza Virus Vaccine in B-Cell Chronic Lymphocytic Leukaemia Patients. Acta Haematol. 1995;53100.

74. Marotta G., Bucalossi A., Egisto P. CD4 + / CD45RA + ‘ Naive ’ T Cells and Immunological Response to Influenza Virus Vaccine in B-Cell Chronic. Acta Haematol. 1998;18–21.

75. Velden A.M.T. Van Der, Mulder A.H.L., Hartkamp A., et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med. 2001;12:420–4.

76. Sun C. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. JAMA Oncol. 2016;2(12):1656–7. DOI:10.1001/jamaoncol.2016.2437.Seasonal.

77. Douglas A.P., A. J., Trubiano, et al. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;397–9.

78. Yawn B.P., Gilden D. The global epidemiology of herpes zoster. Neurology. 2014;81(10):928–30. DOI:10.1212/WNL.0b013e3182a3516e.

79. Dagnew A.F., Ilhan O., Lee W., et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3 , randomised , clinical trial and post-hoc efficacy analysis. Lancet. 2019;3099(19):1–13. DOI:10.1016/S1473-3099(19)30163-X.

80. Guinee V.F., Guido J.J., Pfalzgraf K.A., et al. The incidence of herpes zoster in patients with Hodgkin’s disease an analysis of prognostic factors. Cancer. 1985;56(3):642–8. DOI:10.1002/1097-0142(19850801)56:3<642::AID-CNCR2820560334>3.0.CO;2-N.

81. Nucci M., Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211–25. DOI:10.1086/605664.

82. Hata a., asanuma h., rinki m., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants a bstract Background The reactivation of varicellazoster. N Engl J Med. 2002;347(1):26–34.

83. Insinga R.P., Itzler R.F., Pellissier J.M., et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53. DOI:10.1111/j.1525-1497.2005.0150.x.

84. Habel L.A., Ray G.T., Silverberg M.J., et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82–90. DOI:10.1158/1055-9965.EPI-12-0815.

85. Chanan-Khan A., Sonneveld P., Schuster M.W., et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784–90. DOI:10.1200/JCO.2007.14.9641.

86. Yi Y.-S., Chung J.-S., Song M.-K., et al. The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. Korean J Hematol. 2010;45(3):188. DOI:10.5045/kjh.2010.45.3.188.

87. Rusthoven J.J., Ahlgren P., Elhakim T., et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med. 1988;148(7):1561–6. DOI:10.1001/archinte.148.7.1561.

88. Wade J.S. Viral infections in patients with hematological malignancies. Hematol Am Soc Hematol Educ Progr. 2006;368–74. DOI:10.1007/978-3-319-64263-5_51.

89. Bharucha T., Ming D., Breuer J. A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccines Immunother. 2017;13(8):1–9. DOI:10.1080/21645515.2017.1317410.

90. Boeckh M.J., Arvin A.M., Mullane K.M., et al. Immunogenicity of inactivated varicella zoster vaccine in autologous hematopoietic stem cell transplant recipients and patients with solid or hematologic cancer. Open Forum Infect Dis. 2020;7(7):1–10. DOI:10.1093/ofid/ofaa172.

91. Kim D.K., Hunter P., Woods L.D., et al. Recommended adult immunization schedule, United States, 2019. Ann Intern Med. 2019;170(3):182–92. DOI:10.7326/M18-3600.

92. Pleyer C., Ali M.A., Cohen J.I., et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185–9. DOI:10.1182/blood.2020008758.

93. Rubin L.G., Levin M.J., Ljungman P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3). DOI:10.1093/cid/cit684.

94. Tsigrelis C., Ljungman P. Vaccinations in patients with hematological malignancies. Blood Rev. 2016;30(2):139–47. DOI:10.1016/j.blre.2015.10.001.

95. Yeo W., Chan P.K.S., Ho W.M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22(5):927–34. DOI:10.1200/JCO.2004.05.161.

96. Abdul-Jawad S., Baù L., Alaguthurai T., et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell. 2021; DOI:10.1016/j.ccell.2021.01.001.

97. Приложение N 1 к приказу Министерства здравоохранения РФ от 21 марта 2014 г. № 125н “Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям.”

98. Freedman M.S., Hunter P., Ault K., et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2020. Morb Mortal Wkly Rep Advis. 2020;69(5):133–5. DOI:10.1111/ajt.14244.

99. Rubin L.G., Levin M.J., Ljungman P., et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. 2014;58. DOI:10.1093/cid/cit684.

100. Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect. 2012;18(SUPPL. 5):93–9. DOI:10.1111/j.1469-0691.2012.03971.x.

101. Hilal T., Gea-Banacloche J.C., Leis J.F. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Rev. 2018;32(5):387–99. DOI:10.1016/j.blre.2018.03.004.

102. Vaccinations Recommended for Patients with Chronic Lymphocytic Leukaemia (CLL) and monoclonal B-cell lymphocytosis (MBL). NHS HDFT intranet. September 2018. Available at: https://www.hdft.nhs.uk/services/pathology/clinical-haematology/.